Selank
Russian synthetic heptapeptide marketed for anxiety; limited Western trials.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Russian synthetic heptapeptide marketed for anxiety; limited Western trials.
Evidence Intelligence Score™
- Preclinical
- Pilot human← current
- RCT
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data6.3
- Safety maturityFollow-up depth and adverse-event signal5.3
- Mechanism confidencePathway specificity and clarity6.2
- Clinical readinessDistance to physician-prescribable use5.4
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts3.0
- Long-term dataFollow-up beyond initial trial windows3.6
- Translational confidenceAnimal → human signal preservation6.0
Early human signals exist, primarily from observational and pilot work — directional, not definitive.
Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: directional. The next 12–24 months of registered trials will determine whether the early signal holds.
Mood regulation
1 study- moderateMedvedev VE, Tereshchenko OY, Israelyan AY, et al.
Intranasal Selank reduced anxiety symptoms in GAD with efficacy comparable to standard benzodiazepines and a favorable side-effect profile.
RCTn=502015unreviewed
Cognition & focus
1 study- moderateZozulia AA, Neznamov GG, Siuniakov TS, et al.
Intranasal Selank (peptide analog of tuftsin) improved anxiety scores and attention/memory measures vs placebo and was comparable to medazepam without sedation.
RCTn=622008unreviewed
Cognition & focus
1 regimenNo sedation, no withdrawal; mild local nasal irritation reported. Not approved outside Russia/CIS.
Standard course 14 days in Russian protocols; effects on attention/memory secondary to anxiolytic action.
Mood regulation
1 regimenFavorable tolerability vs benzodiazepines; mild nasal irritation. Not approved outside Russia/CIS.
Short courses; no validated long-term maintenance regimen.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
1 brand across three tiers.
Research-use only
1 brandSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.